8:00 am

Welcome and Introductory Remarks
CCS President
Teresa Zimmers, PhD, Oregon Health & Science University, USA

Clinical Advances in Cancer Cachexia

Session A: State-of-the-Knowledge: Clinical Fundamentals of Cancer Cachexia

Co-Chairs: TBN

8:10 am

Objective metrics for cancer cachexia assessments
TBN

8:40 am

Endpoints in cachexic clinical trials - taking stock, moving forward

Barry Laird, MBChB MRCGP MD - University of Edinburgh, Scotland, UK

9:10 am

Update on consensus definition of cancer cachexia
Vickie Baracos, PhD - University of Alberta, CANADA

9:40 am

Cardiac wasting in advanced cancer & its therapeutic implications
Stefan Anker, PhD MD - Charité Berlin, GERMANY

10:10 am

Break

Session B: Recent Clinical Trials and Trial Results

Co-Chairs: TBN

10:30 am

Ponsegromab as a potential therapy for cancer cachexia
John D. Groarke, MBBCh MSc MPH – Pfizer, Inc.

11:00 am

Central relays in cancer cachexia
Daniel Marks, MD PhD – Oregon Health & Science University, USA

11:30 am

Talk selected from abstract submissions

12:00 pm

Developing a Cachexia Lexicon
Elif Andac-Jones, PhD - Cancer Support Community, USA

12:15 pm

Short talk selected from abstract submissions

12:30 pm

Lunch Break

Considering People with Cancer Cachexia

1:30 pm

Patient-Provider-Caregiver Panel

Chair: Martin Kochanczyk, PhD – Cancer Cachexia Society, USA

History of Cancer Cachexia Research in Scotland

Chair: TBN

3:00 pm

History of cancer cachexia research in Glasgow
Donald McMillan, PhD – University of Glasgow, Scotland, UK

3:25 pm

Cachexia research- the Edinburgh perspective

Stephen Wigmore, Regius Chair of Clinical Surgery – University of Edinburgh, Scotland, UK

3:45 pm

Break

Next Gen Researchers in Cancer Cachexia

• Whisky tasting
• Ghost tour of Edinburgh
• Walking tour of Edinburgh

7:00 am

Mentoring Event

NCI/CRUK Cancer Grand Challenge - CANCAN

Chair: Bette Caan, DrPH - Kaiser Permanente, USA

8:30 am

The role of IL-6 in the C26 cancer cachexia model
Tony Hui, PhD – Harvard University, USA

9:00 am

CANCAN talk 2
Janelle Ayres, PhD – Salk Institute for Biological Studies, USA

9:30 am

The Role of Positron Emission Tomography in Understanding Cancer Cachexia

David Lewis, PhD - Cancer Research Beatson Institute, Scotland, UK

9:45 am

Working Towards a Precision Medicine Framework in Cancer Cachexia: Learning from Patients
Richard Dunne, MD - University of Rochester, USA

10:30 am

Break

Tumor as driver of cachexia

Co-Chairs: TBN

11:00 am

Pancreatic Cancer Cachexia

Min Li, PhD – The University of Oklahoma Health Sciences Center

11:30 am

Modulating Key Metabolic Pathways - Impact on Cachexia and Malnutrition

Bei Zhang, PhD - Pfizer, USA

12:00 pm

Racial/ethnic heterogeneity in cancer cachexia

Jose Trevino, MD - Virginia Commonwealth University, USA

12:30 pm

Short talk selected from abstracts

12:45 pm

Lunch break

Artelo Biosciences Symposium

1:30 pm

Poster Viewing

Cachexia/Muscle wasting as a driver of cancer

Co-Chairs: TBN

4:00 pm

Muscle-tumor crosstalk during cancer cachexia

Bert Blaauw, PhD - Veneto Institute of Molecular Medicine, ITALY

4:30 pm

Host Murf1 deletion preserves muscle and slows pancreatic cancer progression
Andrew Judge, PhD - University of Florida, USA

5:00 pm

Tumor-host cross talk: delineating the reciprocal contribution of muscle wasting to tumor progression

Jason Doles, PhD - Indiana University, USA

5:15 pm

Short talk selected from abstracts

5:30 pm

Short talk selected from abstracts

7:00 pm

*Dinner

9:00 pm

*Cèilidh – a traditional Scottish party

7:00 am

Cachexia Speed Networking

Multi-organ crosstalk in Cancer Cachexia

Co-Chairs: TBN

8:30 am

Gut microbiome alterations and metabolic disorders in acute myeloid leukemia
Laure Bindels, PhD - Université catholique de Louvain, BELGIUM

9:00 am

Tumor - host interactions revealed in drosophila models of cachexia
Tor Erik Rusten, PhD – University of Oslo, NORWAY

9:30 am

Short talk selected from abstract submissions

9:45 am

Short talk selected from abstract submissions

10:00 am

Break

Keynote Address

10:15 am

Introduction of Kenneth Fearon Lecture Speaker
Marie Fallon, MD - University of Edinburgh, Scotland, UK

10:20 am

How Different Environments Can Influence Our Understanding of Muscle Wasting in Cancer Cachexia
Denis Guttridge, PhD - Medical University of South Carolina, USA

Cutting Edge Research in Cancer Cachexia

Co-Chairs: TBN

11:30 am

Cutting Edge Talk 1 from abstracts

11:35 am

Cutting Edge Talk 2 from abstracts

11:40 am

Cutting Edge Talk 3 from abstracts

11:45 am

Cutting Edge Talk 4 from abstracts

11:50 am

Cutting Edge Talk 5 from abstracts

11:55 pm

Cutting Edge Talk 6 from abstracts

12:00 pm

Lunch Break

Immunometabolism of Cancer Cachexia

Co-Chairs: TBN

1:30 pm

Relationships Between Cancer Cachexia, Elevated Drug Clearance, and Immune Checkpoint Inhibitor Response

Chris Coss, PhD - The Ohio State University, USA

2:00 pm

HMGB1 in cancer cachexia
Marco Bianchi, MD - San Raffaele University, ITALY

2:30 pm

IL-6 and adaptive metabolism in cancer cachexia
Aaron Grossberg, MD PhD - Oregon Health & Science University, USA

2:45 pm

Short talk selected from abstract submissions

3:00 pm

Break

Novel targetable pathways, novel therapeutic strategies

Co-Chairs: TBN

3:30 pm

A novel target for tumor growth and muscle wasting
Marco Sandri, PhD - University of Padova, ITALY

4:00 pm

Long noncoding RNAs in the regeneration of aging muscle
Miriam Gorospe, PhD – National Institute on Aging, National Institutes of Health, USA

4:30 pm

Age-related effects creating a permissive environment for sarcopenia

David Glass, MD, PhD – Regeneron Pharmaceuticals Inc., USA

5:00 pm

Heterogeneity of cachexia development in NSCLC

Rodney Infante, MD PhD - University of Texas Southwestern Medical Center, USA

5:30 pm

Short talk selected from abstract submissions

5:45 pm

Presentation of awards

6:00 pm

Closing Remarks
Teresa Zimmers, PhD – Oregon Health & Science University, USA and Andrew Judge, PhD – University of Florida, USA